

Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases



Adult Respiratory Syncytial Virus (RSV) Session

Camille Kotton, MD

Chair, Adult RSV Work Group

Advisory Committee on Immunization Practices (ACIP)

June 26, 2024

Adult RSV Work Group Membership

ACIP Voting Members

Camille Kotton (Chair)
Keipp Talbot
Sarah Long
Albert Shaw

Ex Officio Members

Rachel Zhang (FDA)
Nicholas Geagan (FDA)
Nadine Peart Akindele (FDA)
Sonnie Kim (NIH/NIAID)
Michelle Juaneza (HRSA)
Uzo Chukwuma (IHS)

CDC Co-Leads

Michael Melgar
Amadea Britton

Liaisons

Kenneth Schmader (AGS)
Vidya Sundareshan (ACP)
Gretchen LaSalle (AAFP)
April Killikelly (NACI, PHAC)
Winnie Siu (NACI, PHAC)
Katherine Williams (APTR)
Ruth Lynfield (NFID)
Bindy Crouch (AIM)
Steven Pergam (IDSA)
Elizabeth Skoy (APhA)

Consultants

Robert Atmar (Baylor College of Medicine)
Doug Campos-Outcalt (University of Arizona)
Helen Chu (University of Washington)
Peter Donofrio (Vanderbilt University)
Marie Griffin (Vanderbilt University)
Rebecca Morgan (Case Western Reserve University)
Cynthia Lucero-Obusan (Veterans Health Administration)
Tracy Ruckwardt (NIH/NIAID)
Jonathan Temte (University of Wisconsin)

Transition in Work Group Chair

- Dr. Albert Shaw will be the incoming work group chair for the adult RSV work group starting in July 2024.



CDC Contributors

Coronavirus and Other Respiratory Viruses Division

Melissa Coughlin	Danielle Moulia
Fatima Dawood	Ismael Ortega-Sanchez
Katherine Fleming-Dutra	Lakshmi Panagiotakopoulos
Kristen Folsom	Pragna Patel
Jarrett Gartin	Monica Patton
Monica Godfrey	Amanda Payne
Aron Hall	Derrell Powers
Fiona Havers	Mila Prill
Michele Hlavsa	Lauren Roper
Jefferson Jones	Diya Surie
Ruth Link-Gelles	Natalie Thornburg
Agustin Lopez	Raigan Wheeler
Josephine Mak	Megan Wallace
Meredith McMorrow	Trang Wisard
Noelle-Angelique Molinari	

Immunization Safety Office

Anne Hause
Pedro Moro
Christine Olson
David Shay
Karen Broder
John Su
Eric Weintraub
Michael McNeil
Julianne Gee

Influenza Division

Jill Ferdinands
Lisa Grohskopf

Immunization Services Division

Carla Black
Kayla Calhoun
Jennifer Kriss
James Singleton
Nicole Dowling
Andrew Leidner
Jamison Pike
James Singleton
Patricia Wodi

NCIRD Office of the Director

Hannah Rosenblum
Melinda Wharton
Jessica MacNeil

CDC and ACIP currently recommend that adults aged 60 years and older may receive a single dose of RSV vaccination, using shared clinical decision-making.

- ACIP voted on this recommendation at the June 2023 meeting
- Recommendation is not product-specific; administer whichever vaccine is available



Recap of Adult RSV session, February 2024

- Moderna presented safety and efficacy data from the first 9 months of follow up in their phase 3 trial in adults aged ≥ 60 years
- CDC presented risk-stratified rates of RSV-associated hospitalization in U.S. adults aged 50 years and older
- CDC gave an update on uptake and implementation of RSV vaccine in U.S. adults aged 60 years and older during the first season following the recommendation
- CDC and FDA presented on post-marketing safety of the protein subunit RSV vaccines (GSK's AREXVY and Pfizer's ABRYYSVO) in adults aged 60 years and older
- CDC presented an analysis comparing the estimated magnitude of public health benefit and potential risk of Guillain-Barre syndrome (GBS) associated with protein subunit RSV vaccination in adults aged 60 years and older
- For adults aged 60 years and older who remain unvaccinated, ACIP agreed with encouraging timing of RSV vaccination in the late summer and early fall to optimize public health benefits

Recent work group discussion

- Moderna mRESVIA for use in adults aged 60 years and older (received FDA approval May 31, 2024)
- GSK AREXVY for use in adults aged 50-59 years at increased risk of severe RSV disease (received FDA approval June 7, 2024)
- Continued discussion of safety, including risk of GBS, following RSV vaccination
- Shift from a shared clinical decision-making recommendation to:
 - Potential universal recommendation in adults 75 and older
 - Potential risk-based recommendation in adults 60–74
 - Potential risk-based recommendation in adults 50–59



Re-evaluating Shared Clinical Decision-Making (SCDM) recommendation

- In June 2023, ACIP recommended RSV vaccination in adults 60 and older using shared clinical decision-making
 - In addition to benefits of vaccination, the shared clinical decision-making discussion, as intended by ACIP, is also meant to include discussion of the potential risk of vaccine-associated adverse events associated with RSV vaccine, specifically Guillain Barre Syndrome.
- In the first year following this recommendation, we have learned:
 - Feedback from healthcare providers that having SCDM conversations is not simple in practice.
 - Unlike a universal recommendation where there's a clear call to action to vaccinate, with SCDM the call to action is to discuss with a healthcare provider, a less clear message.
- A risk-based recommendation for adults 60–74 and a universal recommendation for adults ≥ 75 years would potentially highlight more clearly for providers and other public health officials which adults are likely to benefit from an RSV vaccine and provide a clearer recommendation for patients.

Agenda: Wednesday June 26, 2024

- Manufacturer presentation: ABRYOVO (Pfizer) safety and immunogenicity in non-pregnant adults aged 18-59 years
- Manufacturer presentation: AREXVY (GSK) immunogenicity with a 24-month revaccination interval
- Manufacturer presentation: mRESVIA (Moderna) season 2 safety and efficacy update
- Postmarketing safety updates: Vaccine Safety Datalink
- Evaluation of Guillain-Barre Syndrome (GBS) following RSV vaccination among adults 65 years and older
- Observational RSV vaccine effectiveness
- Economic analysis of adult RSV vaccination
- Update to benefits and risks discussion
- Comparison of economic analyses of adult RSV vaccination
- Evidence to Recommendations
- Clinical Considerations
- Dr. Iona Munjal (Pfizer)
- Dr. Susan Gerber (GSK)
- Dr. Rituparna Das (Moderna)
- Dr. James Donahue (Marshfield Clinic Research Institute)
- Dr. Patricia Lloyd (FDA)
- Dr. Diya Surie (CDC, NCIRD)
- Dr. David Hutton (University of Michigan)
- Dr. David Hutton (University of Michigan)
- Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
- Dr. Michael Melgar (CDC/NCIRD), Lauren Roper (CDC/NCIRD), Dr. Amadea Britton (CDC/NCIRD)
- Dr. Michael Melgar (CDC/NCIRD)

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

